PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1782021
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1782021
Minimally Invasive Biopsy Techniques Market size was valued at US$ 13,146.12 Million in 2024, expanding at a CAGR of 10.5% from 2025 to 2032.
Minimally invasive biopsy techniques refer to procedures that obtain tissue samples for diagnostic purposes through smaller incisions and with less damage to surrounding tissue than traditional surgical biopsies. These methods present benefits such as diminished scarring, quicker recovery times, and a lower likelihood of complications. Frequently utilized techniques include fine-needle aspiration (FNA), core needle biopsy (CNB), and vacuum-assisted biopsy (VAB), which are often performed with the assistance of imaging technologies such as ultrasound, MRI, or mammography. Overall, minimally invasive biopsy techniques represent a significant advancement in tissue sampling, delivering precise diagnoses while minimizing the burden on patients.
Minimally Invasive Biopsy Techniques Market- Market Dynamics
The increasing global prevalence of cancer, along with the growing significance of precision diagnostics, is anticipated to propel market growth.
As the incidence of cancer continues to rise globally, there is an urgent requirement for early, precise, and less invasive diagnostic methods. Minimally invasive biopsy techniques, including fine-needle aspiration, core needle biopsy, and liquid biopsy, provide quicker recovery times, decreased patient discomfort, and lower rates of complications when compared to conventional surgical approaches. The World Health Organization estimates that the number of new cancer cases is expected to reach 35 million by 2050, which signifies a 77% increase from the 20 million cases documented in 2022. Nevertheless, increasing investments in oncology research, personalized medicine, and healthcare innovation may present opportunities for market expansion. Furthermore, the high costs associated with advanced biopsy systems could hinder market growth.
Minimally Invasive Biopsy Techniques Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.5% over the forecast period (2025-2032)
Based on Product Offered segmentation, Kits & Consumables were predicted to show the maximum market share in the year 2024
Based on Technique segmentation, Liquid Biopsy was the leading Technique in 2024
Based on Circulating Biomarker segmentation, cell-free DNA (cfDNA) was the leading Circulating Biomarker in 2024
Based on Application segmentation, Clinical was the leading Application in 2024
Based on end-user segmentation, Hospitals and clinics were the leading end users in 2024
Based on region, North America was the leading revenue generator in 2024
The Global Minimally Invasive Biopsy Techniques Market is segmented based on Product Offered, Technique, Circulating Biomarker, Application, End User, and Region.
The market is divided into three segments according to the Products Offered: Tests, Kits & Consumables, and Instruments. Kits & Consumables occupy a leading role in the market, attributed to their frequent usage, disposability, and essential function in ensuring sterile and accurate diagnostic procedures. This category encompasses biopsy needles, forceps, syringes, reagents, and sample collection containers, all of which are vital for various biopsy methods, including fine-needle aspiration, core needle biopsy, and vacuum-assisted biopsy. The ongoing demand for these products in hospitals, diagnostic laboratories, and outpatient settings significantly boosts their substantial market share.
The market is categorized into four segments based on Technique: Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, and Others. Liquid Biopsy is at the forefront of market expansion, owing to its capability to identify cancer-related biomarkers through a straightforward blood draw, providing a safer, quicker, and more patient-centric alternative to conventional tissue biopsies. It facilitates real-time monitoring of disease progression, early cancer detection, and evaluation of treatment responses without requiring invasive procedures. The growing adoption of precision medicine and the increasing demand for early cancer diagnostics are propelling the swift growth and acceptance of liquid biopsy in various clinical environments.
The market is categorized into four segments based on circulating Biomarkers: Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, and Others. Cell-Free DNA (cfDNA) is the primary driver of market growth. Within the liquid biopsy sector, cell-free DNA (cfDNA) is at the forefront of market expansion due to its essential function in non-invasive cancer diagnostics and monitoring. By analyzing fragments of DNA released by tumors into the bloodstream, cfDNA facilitates the identification of genetic mutations, tumor burden, and treatment resistance. Its capacity to deliver real-time insights into tumor dynamics without requiring surgical interventions has established it as a fundamental element in precision oncology.
The market is segmented into two categories according to Application: Clinical and Therapeutic. Clinical is the primary driver of market growth. Clinical applications are at the forefront of market expansion in minimally invasive biopsy techniques, propelled by the rising adoption of these procedures in standard diagnostics and disease monitoring. Hospitals, diagnostic laboratories, and specialty clinics are progressively employing minimally invasive techniques such as liquid biopsy, fine-needle aspiration, and image-guided biopsies for early detection and tailored treatment planning, especially in the field of oncology.
The market is segmented into three categories based on End-User: Hospitals & Clinics, Academic & Research Institutions, and Ambulatory Care Centers. Hospitals and clinics are at the forefront of market growth among end users in the minimally invasive biopsy techniques sector, attributed to the high patient volume, the presence of advanced diagnostic facilities, and the expertise of medical professionals. These environments serve as the primary point of care for disease detection, particularly in oncology, where procedures such as fine-needle aspiration, core needle biopsy, and liquid biopsy are commonly conducted. Academic and research institutions also play a vital role, concentrating on the advancement of innovative biopsy methods and the discovery of biomarkers. In contrast, ambulatory care centers are witnessing an increase in adoption due to the growing preference for outpatient, cost-effective, and minimally invasive procedures that offer faster recovery times.
Minimally Invasive Biopsy Techniques Market- Geographical Insights
North America leads in market growth, primarily due to the increasing adoption of liquid biopsy. The rising incidence of cancer, along with a strong focus on early and accurate diagnosis, has expedited the incorporation of liquid biopsy into clinical practices. Furthermore, the presence of prominent biotechnology firms, sophisticated healthcare infrastructure, and supportive regulatory frameworks has further propelled market growth. The United States (US), with a population exceeding 330 million, benefits from one of the most intricate healthcare systems globally, characterized by the interconnected relationships among providers, payers, and patients receiving care. Europe ranks as the second largest region for market growth, attributed to advancements in imaging and navigation technologies.
The competitive environment of the Minimally Invasive Biopsy Techniques Market is characterized by the participation of various established medical device manufacturers, diagnostic firms, and emerging biotech startups. Leading companies are developing advanced imaging-guided, robotic-assisted, and AI-integrated biopsy solutions designed to enhance accuracy and reduce procedural risks. Organizations are investing in non-invasive liquid biopsy technologies, especially those focusing on circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA), to enable real-time cancer monitoring. Furthermore, companies are broadening their operations in the Asia-Pacific and Latin America regions to take advantage of the growing demand for less invasive diagnostic approaches.
On January 22, 2025, GRACE Breast Imaging & Medical Spa of Iowa, located in Urbandale and Clive, achieved a significant milestone by becoming the first healthcare facility in the United States to install the innovative Mammomat B.brilliant. This marks the first complete redesign of a mammography platform by Siemens Healthineers in over ten years. The Mammomat B.brilliant incorporates advanced 3D image acquisition and image reconstruction technology, along with capabilities for full-field digital mammography, which includes two-dimensional breast imaging, breast biopsy, and titanium contrast-enhanced mammography.